Pfizer

Oncology Research and Development Postdoctoral Program

Michael A. White, Ph.D.
VP/CSO Tumor Cell Biology, Pfizer Oncology R&D

Education

Undergrad: B.S., Zoology, University of Iowa, Iowa City
Graduate: Ph.D. , Biology, University of North Carolina, Chapel Hill
Postdoctoral training: Cold Spring Harbor Laboratory, NY

Research Interests:

Mike's science has focused on oncogenic Ras effector networks, the molecular architecture of mitogenic signaling pathways; functional annotation of cancer genomes; and genomics-guided intervention target discovery.

Selected Publications

Kim J, McMillan E, Kim HS et al. XPO1-dependent nuclear export is druggable vulnerability in KRAS-mutant lung cancer. Nature, 538, 114-117 (2016).

Kim HS, Mendiratta S, Kim J, et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell, 155, 552-566 (2013).

 Bodemann BO, Orvedahl A, Cheng T et al. RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly. Cell, 144, 253-267 (2011).

Whitehurst AW, Bodemann BO, Cardenas J et al. Synthetic lethal screen identification of chemosensitizerloci in cancer cells. Nature, 446, 815-819 (2007).